In conclusion, our study revealed the significant association between clinical variables (old age, squamous cancer, and anti-PD-L1 treatment), radiological response, and immune cells from peripheral blood and MPR in patients with NSCLC receiving 2–4 cycles of neoadjuvant CAPD. The gene discussed is CD274; the disease is non-small cell lung carcinoma.